Text Size

Tolerability and pharmacokinetics of intravitreal sirolimus

Mudumba S., Bezwada P., Takanaga H., Hosoi K., Tsuboi T., Ueda K., Kawazu K., Ali Y., Naor J.


  • 2012
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Pharmaceutical and Preclinical Development Department, Santen Incorporated, 2100 Powell Street, Emeryville, CA 94608, United States; Santen Pharmaceutical Co, Ltd., Ikoma-shi, Nara, Japan

Related Publications

Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Tajima H., Honda T., Kawashima K., Sasabuchi Y., Yamamoto M., Ban M., Okamoto K., Inoue K., Inaba T., Takeno Y., Aono H.


Valosin-containing protein modulator KUS121 protects retinal neurons in a rat model of anterior ischemic optic neuropathy

Kikkawa C., Ikeda H.O., Hata M., Iwai S., Tsujikawa A.


Rapid and efficient generation of mature retinal organoids derived from human pluripotent stem cells via optimized pharmacological modulation of Sonic hedgehog, activin A, and retinoic acid signal transduction

Matsushita T.; Onishi A.; Matsuyama T.; Masuda T.; Ogino Y.; Kageyama M.; Takahashi M.; Uchiumi F.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022